NCT00474994 · OUTCOME

Overall Objective Response

Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas · Source last updated 2016-01-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

as assessed by RECIST criteria

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas	48

Partial Response (PR)

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas	1	Not reported	Not reported	Not reported	Not reported

Stable Disease (SD)

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas	21	Not reported	Not reported	Not reported	Not reported

Progression of Disease (POD)

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas	26	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

as assessed by RECIST criteria

groups

param Type

NUMBER

reporting Status

POSTED

time Frame

2 years

title

Overall Objective Response

type

PRIMARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice